Compound: Medroxyprogesterone acetate
SMILES: O=C1C=C2[C@]([C@@H]3[C@H]([C@H]4[C@]([C@@](OC(=O)C)(C(=O)C)CC4)(C)CC3)C[C@@H]2C)(C)CC1
InChIKey: PSGAAPLEWMOORI-PEINSRQWSA-N
Synonyms: Medroxyprogesterone acetate, 71-58-9, Medroxyprogesterone 17-acetate, Provera, Depo-Provera, Metigestrona, Farlutin, Clinovir, Gestapuran, Lutopolar, Perlutex, Oragest, Veramix, Amen, Methylacetoxyprogesterone, Medroxyacetate progesterone, Progestalfa, Clinofem, Nadigest, Nidaxin, Prodasone, Progevera, Proverone, Repromix, Sirprogen, Hysron, Depo-clinovir, Depo-progestin, Depot-medroxyprogesterone acetate, NSC-26386, Repromap, Provera dosepak, Depo-Progevera, 6-alpha-Methyl-17-alpha-acetoxyprogesterone, Cycrin, MAP (steroid), Depo-Subq Provera 104, 6-alpha-Methyl-17-alpha-hydroxyprogesterone acetate, Aragest, Farlutal, 17alpha-Hydroxy-6alpha-methylprogesterone acetate, 6alpha-Methyl-17alpha-hydroxyprogesterone acetate, Depo-subq provera, Depot medroxyprogesterone acetate, 6alpha-Methyl-4-pregnene-3,20-dion-17alpha-ol acetate, 17-Acetoxy-6alpha-methylprogesterone, 6alpha-Methyl-17-acetoxyprogesterone, 6alpha-Methyl-17-acetoxy progesterone, Depo-Medroxyprogesterone acetate, Nogest, C2QI4IOI2G, Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6alpha)-, NSC-21171, 17-Acetoxy-6-alpha-methylprogesterone, U 8839, 6-alpha-Methyl-17-acetoxy progesterone, DTXSID0025527, (6alpha)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dione, 17-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione acetate, Medroxyprogesteroni acetas, Progesterone, 17-hydroxy-6alpha-methyl-, acetate, 17-alpha-Hydroxy-6-alpha-methylprogesterone acetate, TV-46046, 17-alpha-Acetoxy-6-alpha-methylpregn-4-ene-3,20-dione, 6-alpha-Methyl-17-alpha-acetoxypregn-4-ene-3,20-dione, Progesterone, 17-alpha-hydroxy-6-alpha-methyl-, acetate, g-Farlutal, Medroxyprogesterone 17 Acetate, (6alpha)-6-methyl-3,20-dioxopregn-4-en-17-yl acetate, CHEBI:6716, DTXCID905527, 17alpha-Acetoxy-6alpha-methylprogesterone, 6-alpha-Methyl-4-pregnene-3,20-dion-17-alpha-ol acetate, 17-alpha-Hydroxy-6-alpha-methylpregn-4-ene-3,20-dione acetate, NSC21171, NSC26386, (6-alpha)-Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, Pregn-4-ene-3,20-dione, 17-hydroxy-6alpha-methyl-, acetate, Metipregnone, PREMPRO COMPONENT MEDROXYPROGESTERONE ACETATE, 6alpha-Methyl-3,20-dioxopregn-4-en-17-yl acetate, PREMPHASE COMPONENT MEDROXYPROGESTERONE ACETATE, Sodelut G, Ciclotal, Climanor, DepoProvera, Sayana press, Depo Provera, Nadigest (vet), Nidaxin (vet), Farlutal 100, Farlutal 200, Farlutal 250, Farlutal 500, Depo-provera oncology, RefChem:810842, 6-alpha-Methyl-17alpha-hydroxyprogesterone Acetate, Depo Medroxyprogesterone Acetate, Depot-Medroxyprogestereone Acetate, 6-Alpha-methyl-17alpha-acetoxyprogesterone, Medroxyprogesterone Acetate Injectable Suspension, 6 alpha Methyl 17alpha hydroxyprogesterone Acetate, 17-(Acetyloxy)-6alpha-methylpregn-4-ene-3,20-dione, (6 alpha)-17-(Acetoxy)-6-methylpregn-4-ene-3,20-dione, (6alpha)-17-(Acetyloxy)-6-methylpregn-4-ene-3,20-dione, (1S,2R,8S,10R,11S,14R,15S)-14-acetyl-2,8,15-trimethyl-5-oxotetracyclo(8.7.0.02,7.011,15)heptadec-6-en-14-yl acetate, 200-757-9, NSC-27408, Deporone, Depo-Promone, Depcorlutin, Supprestral, Promone-E, Medroxyprogesteroneacetate, DP150, Ralovera, Medroxyprogesterone-17-acetate, Depo-Ralovera, MFCD00010483, MLS000069442, MLS001148217, Indivina, Medroxy Progesterone 17-Acetate, ONCO-Provera, Depo-Prodasone, Depomedroxyprogesterone acetate, Aragest 5, Med-Pro, Medroxyprogesterone acetate (Standard), 17alpha-acetoxy-6alpha-methylpregn-4-ene-3,20-dione, (6S,8R,9S,10R,13S,14S,17R)-17-Acetyl-6,10,13-trimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate, [(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate, 6alpha-Methyl-17alpha-acetoxyprogesterone, Medrosterona, Cykrina, Depocon, Mepastat, Meprate, SMR000059125, Sumiferm, Suprestral, Veraplex, Dugen, Perlutex Leo, Depo-Map, MPA-beta, MPA Hexal, MPA-Noury, MPA GYM, CAS-71-58-9, CCRIS 371, 17.alpha.-Acetoxy-6.alpha.-methylprogesterone, Medroxyprogesterone acetate [JAN], EINECS 200-757-9, UNII-C2QI4IOI2G, NSC 21171, Depo-Provera Contraceptive, (6.alpha.-Pregn-4-ene-3, 17-(acetyloxy)-6-methyl-, 17.alpha.-Hydroxy-6-.alpha.-methylprogesterone acetate, Pregn-4-ene-3, 17-hydroxy-6.alpha.-methyl-, acetate, BRN 2066112, Pregn-4-ene-3, 17-(acetyloxy)-6-methyl-, (6.alpha.)-, AI3-60127, Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6.alpha.)-, 17-Acetoxy-6.alpha.-methylprogesterone, 6.alpha.-Methyl-17-acetoxyprogesterone, NCGC00094713-01, 17alpha-Hydroxy-6-alpha-methylprogesterone acetate, CBP-1011, Provera (TN), Depo-provera (TN), 6alpha-Methyl-17alpha-acetoxypregn-4-ene-3,20-dione, Medroxyprogesterone acetate [USP:JAN], 17alpha-Acetoxy-6-alpha-methylpregn-4-ene-3,20-dione, Medroxyprogesterone acetate [Progestins], 6.alpha.-Methyl-17.alpha.-acetoxyprogesterone, Medroxyprogesone acetate, (6-alpha)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dione, 17alpha-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione acetate, 6alpha-Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, CPD000653524, Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6a)-, Opera_ID_1110, medroxyprogesterone-acetate, 17.alpha.-Hydroxy-6.alpha.-methylprogesterone acetate, 6.alpha.-Methyl-17.alpha.-hydroxyprogesterone acetate, CHEMBL717, SCHEMBL4276, 6.alpha.-Methyl-17.alpha.-acetoxypregn-4-ene-3,20-dione, 17.alpha.-Acetoxy-6-.alpha.-methylpregn-4-ene-3,20-dione, 4-08-00-02212 (Beilstein Handbook Reference), 6.alpha.-Methyl-4-pregnene-3,20-dion-17.alpha.-ol acetate, MLS002207115, Medroxyprogesterone acetate RS, 17.alpha.-Hydroxy-6.alpha.-methylpregn-4-ene-3,20-dione acetate, Medroxyprogesterone acetate CRS, Depo-subq provera 104 (TN), orb1309193, orb3139831, HY-B0469R, MSK2210, HMS2233O07, HMS2235E05, HMS3259O14, HMS3884B10, 17?-Acetoxy-6?-methylprogesterone, HY-B0469, Tox21_111319, Tox21_200141, BDBM50067678, EBC-26889, MSK2210-100A, s2567, AKOS015894870, MSK2210-1000A, Tox21_111319_1, AC-2174, CCG-264965, DB00603, FM25036, NC00574, Medroxyprogesterone acetate (JP18/USP), MRF-0000023, NCGC00022037-03, NCGC00022037-04, NCGC00022037-05, NCGC00022037-07, NCGC00257695-01, NCGC00263480-01, (1R,3aS,3bR,5S,9aR,9bS,11aS)-1-acetyl-5,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl acetate, AS-13981, MEDROXYPROGESTERONE ACETATE [IARC], SMR000653524, SY077009, MEDROXYPROGESTERONE ACETATE [MART.], MEDROXYPROGESTERONE ACETATE [VANDF], MEDROXYPROGESTERONE 17-ACETATE [MI], MEDROXYPROGESTERONE ACETATE [USP-RS], MEDROXYPROGESTERONE ACETATE [WHO-DD], MEDROXYPROGESTERONE ACETATE [WHO-IP], CS-0694837, NS00006415, C08150, C76275, D00951, 17?-Acetoxy-6?-methylpregn-4-ene-3,20-dione, AB00384270-14, AB00384270_15, EN300-7480751, Medroxyprogesterone 17-acetate, >=97% (HPLC), MEDROXYPROGESTERONE ACETATE [ORANGE BOOK], Medroxyprogesterone acetate for system suitability, MEDROXYPROGESTERONI ACETAS [WHO-IP LATIN], F787593, MEDROXYPROGESTERONE ACETATE [EP MONOGRAPH], MEDROXYPROGESTERONE ACETATE [USP MONOGRAPH], Medroxyprogesterone acetate for peak identification, MEGESTROL ACETATE IMPURITY A [EP IMPURITY], 17|_-Acetoxy-6|_-methylpregn-4-ene-3,20-dione, LUNELLE COMPONENT MEDROXYPROGESTERONE ACETATE, Q2823834, 6.alpha.-Pregn-4-ene-3, 17-(acetyloxy)-6-methyl-, Medroxyprogesterone acetate for peak identification CRS, Medroxyprogesterone acetate for system suitability CRS, (6?)-17-(Acetyloxy)-6-methyl-pregn-4-ene-3,20-dione, Medroxyprogesterone acetate Solution in Acetonitrile, 1000ug/mL, Medroxyprogesterone acetate Solution in Acetonitrile, 100ug/mL, Medroxyprogesterone Acetate; Megestrol Acetate EP Impurity A, Medroxyprogesterone-17-acetate 100 microg/mL in Acetonitrile, Medroxyprogesterone 17-acetate, VETRANAL(TM), analytical standard, Medroxyprogesterone Acetate Working Standard (Secondary Reference Standard), Medroxyprogesterone acetate, European Pharmacopoeia (EP) Reference Standard, Medroxyprogesterone Acetate, Pharmaceutical Secondary Standard; Certified Reference Material, Medroxyprogesterone acetate, United States Pharmacopeia (USP) Reference Standard, 1301724-98-0, Medroxyprogesterone 17-acetate; 17|A-Acetoxy-6|A-methylprogesterone; 17|A-Hydroxy-6|A-methyl-4-pregnene-3,20-dione 17-acetate; 6|A-Methyl-17|A-acetoxyprogesterone; 6|A-Methyl-17|A-hydroxyprogesterone acetate, Medroxyprogesterone acetate for peak identification, European Pharmacopoeia (EP) Reference Standard, Medroxyprogesterone acetate for system suitability, European Pharmacopoeia (EP) Reference Standard
Theoretical properties:
molecular_formula: C24H34O4
molecular_weight: 386.5 g/mol
exact_mass: 386.24570956 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 0
hydrogen_bond_acceptor_count: 4
rotatable_bond_count: 3
heavy_atom_count: 28
topological_polar_surface_area: 60.4 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
melting_point: 405 to 408 °F (NTP, 1992)
solubility: less than 1 mg/mL at 73 °F (NTP, 1992)
Descriptions:
{"pubchem": "Medroxyprogesterone Acetate can cause cancer according to The World Health Organization's International Agency for Research on Cancer (IARC). It can cause developmental toxicity according to state or federal government labeling requirements.", "chebi": "An acetate ester resulting from the formal condensation of the 17\u03b1-hydroxy group of medroxyprogesterone with the carboxy group of acetic acid. A widely used progestin in menopausal hormone therapy and in progestogen-only birth control.", "chembl": "MEDROXYPROGESTERONE ACETATE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.", "wikipedia": "Medroxyprogesterone acetate (MPA), also known as depot medroxyprogesterone acetate (DMPA) in injectable form and sold under the brand name Depo-Provera among others, is a hormonal medication of the progestin type. It is used as a method of birth control and as a part of menopausal hormone therapy. It is also used to treat endometriosis, abnormal uterine bleeding, paraphilia, and certain types of cancer. The medication is available both alone and in combination with an estrogen. It is taken by mouth, used under the tongue, or by injection into a muscle or fat.\nCommon side effects include menstrual disturbances such as absence of periods, abdominal pain, and headaches. More serious side effects include bone loss, blood clots, allergic reactions, and liver problems. Use is not recommended during pregnancy as it may harm the baby. MPA is an artificial progestogen, and as such activates the progesterone receptor, the biological target of progesterone. It also has androgenic activity and weak glucocorticoid activity. Due to its progestogenic activity, MPA decreases the body's release of gonadotropins and can suppress sex hormone levels. It works as a form of birth control by preventing ovulation.\nMPA was discovered in 1956 and was introduced for medical use in the United States in 1959. It is on the World Health Organization's List of Essential Medicines. MPA is the most widely used progestin in menopausal hormone therapy and in progestogen-only birth control. DMPA is approved for use as a form of long-acting birth control in more than 100 countries. In 2023, it was the 257th most commonly prescribed medication in the United States, with more than 1 million prescriptions."}